Wishdom schreef op 20 maart 2012 17:30:
Deuze gasten benne ook goed bezig.
Dyax Corp. : Dyax Kicks Off Fundraising Activities in Honor of First Ever HAE Day — A Global Event to Raise Awareness of Hereditary Angioedema
03/20/2012 | 10:58am
Company raises $17,700 for the United States Hereditary Angioedema Association at the American Academy of Allergy, Asthma and Immunology Annual Meeting
BURLINGTON, Mass.--(BUSINESS WIRE)-- In honor of the first ever HAE Day upcoming on May 16, 2012, Dyax Corp. (NASDAQ: DYAX), the manufacturer of KALBITOR® (ecallantide) for the treatment of acute attacks of HAE in patients 16 years of age and older, announced a donation of $17,700 to the United States Hereditary Angioedema Association (HAEA), the largest Hereditary Angioedema (HAE) patient group in the world. The donation results from fundraising activities held at the American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting in Orlando, FL, where Dyax dedicated a significant portion of their booth to recognizing HAE Global Awareness Day on May 16, 2012 and raising funds to support the HAEA.
The Dyax booth at AAAAI featured two treadmills on which meeting attendees were invited to walk or run to benefit the HAEA. The company pledged $100 to the HAEA for every mile clocked by meeting attendees, which included clinicians, academicians and allied health professionals, with participants logging nearly 200 miles for the cause. One particularly enthusiastic physician ran ten miles, generating a single donation of $1,000. The fundraiser was the first in a series of events supported by Dyax and will culminate in a donation presented to the HAEA on HAE Day, taking place on May 16, 2012.
"Our fundraising efforts at AAAAI gave us an opportunity not only to engage those physicians who regularly treat HAE, but also some who may not be as familiar with the condition," said Gustav Christensen, President and CEO of Dyax. "We were thrilled to kick off our HAE Day fundraising activities with such a successful event, while raising awareness of the condition among some healthcare professionals who may not know its signs and symptoms."
HAE is a potentially life threatening condition in which patients have a defect in the gene that controls a blood protein called C1 Inhibitor. It is often unrecognized or misdiagnosed because it is so rare, and because its symptoms are similar to many other, more common conditions such as allergic reaction, angina, rheumatism, or acute appendicitis. The lack of an accurate diagnosis can have serious consequences. Patients with undiagnosed HAE may undergo unnecessary medical procedures (e.g., appendectomy, exploratory laparotomy) or receive ineffective treatments.
The US HAE Association and our members are grateful for Dyax's on-going efforts to raise awareness of HAE," said Janet Long, Executive Vice President, HAEA. "We also appreciate the fundraising support that will further our mission to help patients and their families achieve lifelong health."
The United States Senate recently passed a resolution recognizing May 16, 2012 as Hereditary Angioedema Awareness Day. This historic day aims to raise awareness of HAE among the general public and medical community, in order to promote better care and earlier, more accurate diagnosis. For more information about HAE Day, please visit
www.haea.org.